Claims
- 1. (canceled)
- 2. A process for selecting phage that are resistant to blood inactivation, comprising:
a) mixing a blood component with a phage display library; and, b) selecting for phage which are resistant to inactivation by the blood component.
- 3. A process for determining epitopes associated with specific parenchymal cells, comprising:
a) preparing epitope display particles that are sized to exit a blood vessel and contact parenchymal cells; b) inserting the epitope display particles into a blood vessel; and, c) exposing the epitope display particles to the parenchymal cells where the epitope display particles associate with peptides specific to a cell; d) identifying cell specific epitopes.
- 4. The process of claim 1 wherein selection comprises multiple rounds of selection.
- 5. The process of claim 1 wherein the phage display library comprises T7 phage.
- 6. The process of claim 1 wherein the blood component is mixed with the phage display library in vitro.
- 7. The process of claim 1 wherein the blood component is mixed with the phage display library in vivo.
- 8. The process of claim 1 wherein a variable part of the phage DNA sequence is identified.
- 9. A phage that inhibits inactivation by blood components, comprising a phage having a coat peptide that protects the phage from antibody attack and inactivation.
- 10. The phage of claim 8 wherein the coat peptide carboxy terminus comprises a lysine or an arginine.
- 11. The phage of claim 8 wherein the peptide comprises a clone 20-6 peptide.
- 12. The process of claim 1 further comprising determining phage coat peptide interactions with antibodies using the selected phage.
- 13. The process of claim 11 wherein the selected phage is affinity purified.
- 14. The process of claim 11 wherein a phage coat protein's sequence is determined
- 15. A peptide for complexing with a drug to protect the drug from antibody inactivation during delivery, comprising determining a phage coat peptide sequence from the phage selected in claim 1 and associating the peptide with the drug to be delivered.
- 16. The peptide of claim 14 wherein the peptide contains a carboxy terminal amino acid selected from the group consisting of arginine and lysine.
- 17. The peptide of claim 14 wherein the peptide contains a tyrosine.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001]1(Provisional application Ser. No.)(Filing Date)60/131,151Apr. 27, 199960/139,431Jun. 7, 1999
FEDERALLY SPONSORED RESEARCH
[0002] This invention was made under a contract with an agency of the United States Government: U.S. Government agency: NIH Government contract number: 5 R21 DK53314-02
Provisional Applications (2)
|
Number |
Date |
Country |
|
60131151 |
Apr 1999 |
US |
|
60139431 |
Jun 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09559021 |
Apr 2000 |
US |
Child |
10795676 |
Mar 2004 |
US |